Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer

ObjectivesIn randomized-controlled crossover design trials, overall survival (OS) treatment effect estimates are often confounded by the control group benefiting from treatment received post-progression. We estimated the adjusted OS treatment effect in EMPOWER-Lung 1 (NCT03088540) by accounting for...

Full description

Bibliographic Details
Main Authors: Josephine Louella Feliciano, Dylan McLoone, Yingxin Xu, Ruben G.W. Quek, Andreas Kuznik, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel, Patricia Guyot, Gerasimos Konidaris, Keith Chan, Sam Keeping, Florence R. Wilson, Nick Freemantle
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
first-line treatment
cemiplimab
crossover design
EMPOWER-lung 1
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1081729/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1081729/full

Similar Items